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Abstract 
Purpose: To develop and optimise some variables that influence fluoxetine orally disintegrating tablets 
(ODTs) formulation. 
Methods: Fluoxetine ODTs tablets were prepared using direct compression method. Three-factor, 3-
level Box-Behnken design was used to optimize and develop fluoxetine ODT formulation. The design 
suggested 15 formulations of different lubricant concentration (X1), lubricant mixing time (X2), and 
compression force (X3) and then their effect was monitored on tablet weight (Y1), thickness (Y2), 
hardness (Y3), % friability (Y4), and disintegration time (Y5).  
Results: All powder blends showed acceptable flow properties, ranging from good to excellent. The 
disintegration time (Y5) was affected directly by lubricant concentration (X1). Lubricant mixing time (X2) 
had a direct effect on tablet thickness (Y2) and hardness (Y3), while compression force (X3) had a direct 
impact on tablet hardness (Y3), % friability (Y4) and disintegration time (Y5). Accordingly, Box-Behnken 
design suggested an optimized formula of 0.86 mg (X1), 15.3 min (X2), and 10.6 KN (X3). Finally, the 
prediction error percentage responses of Y1, Y2, Y3, Y4, and Y5 were 0.31, 0.52, 2.13, 3.92 and 3.75 %, 
respectively. Formula 4 and 8 achieved 90 % of drug release within the first 5 min of dissolution test.  
Conclusion: Fluoxetine ODT formulation has been developed and optimized successfully using Box-
Behnken design and has also been manufactured efficiently using direct compression technique. 
 
Keywords: Box-Behnken experimental design, Orally disintegrating tablets, Direct compression, 
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Up to one-third of people in all age groups have 
experienced swallowing issues during their 
lifetime [1]. The increased prevalence of 
swallowing issues and the development of 
clinically significant dysphasia (difficulty in 
swallowing) can be observed with increasing 
age, intensity of care required, and the number of 
diseases as well as diseases with dysphasia 
inducing co-morbidity [2]. ODTs greatly improve 
patients’ compliance as it is easily taken without 
the need of water. It provides very rapid onset of 
action for patients in which it promote pregastric 
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absorption of the drug molecules through buccal, 
sublingual, oropharyngeal, and esophageal 
membranes. Moreover, it avoids the first-pass 
hepatic metabolism leads to elevate 
bioavailability and reduces drug side effects [3]. 
 
Some manufacturing technologies of ODTs 
include direct compression, wet granulation, and 
lyophilization [3]. The direct compression method 
is the easiest and cost-effective method for the 
production of ODTs [4,5]. Lubrication is a critical 
element in tablet formulation. Lubricants are 
used to diminish the friction and adhesion of the 
powder blend to the punches and die wall [6]. 
Magnesium stearate is considered as the most 
common, chemically stable, and metallic salt 
boundary lubricant with high melting point, but it 
is hydrophobic [7]. Hence, lubricant 
concentration has been reported as one of the 
independent variables for experimental design 
[5,8,9]. In ODTs, it is important to keep quick 
disintegration properties of the tablets with 
adequate hardness [10]. Thus, optimizing the 
amount of magnesium stearate and mixing time 
is critical in the manufacturing of ODTs [5].  
 
Optimization is a procedure that exploits 
available resources to obtain the best possible 
results. The manner of try and error that was 
extensively used before is now switched by the 
optimization system that finds a wide range of 
application in chemistry and pharmaceutical 
industry in the meantime [11]. Response surface 
methodology (RSM) is an assembly of 
mathematics and statistics procedures that is 
quite beneficial for the analysis and modelling of 
problems in which the optimized response of 
interest is influenced by numerous variables and 
objectives [12]. Box-Behnken experimental 
design offers 3 levels for each factor and 
involves a particular subsection of factorial 
blends from the 3k factorial design [12,13].  
 
Optimization techniques have been employed by 
several researchers in the design and 
development of ODTs [14, 15]. However, some 
researchers had developed and prepared 
fluoxetine HCl in ODTs formulation using try and 
error methodology and they also used either wet 
granulation or sublimation techniques in order to 
manufacture the fluoxetine ODTs [16–18]. 
Consequently, this Box-Behnken experimental 
design will be the technique of choice to develop 
and optimize the fluoxetine ODTs. The design 
helps to develop the work methodology of 
fluoxetine ODTs. The design can minimize the 
number of trials, time, money, and gives 
developed formulation.   
The World Health Organization has listed 
fluoxetine as an essential medicine [19]. 
Fluoxetine is a selective serotonin reuptake 
inhibitor indicated in the treatment of major 
paediatric depression, adults and children 
obsessive compulsion disorder, panic, 
premenstrual dysphoric disease, autism in adult, 
and trichotillomania [20,21]. The bioavailability of 
fluoxetine after oral administration has been 
reported to be up to 72 %, and the elimination of 
half-life ranged between 1 to 4 days [22]. 
Fluoxetine HCl is nominated for this work 
because it is widely used as antidepressant drug.  
In the present study, direct compression 
technique was used to prepare fluoxetine ODTs 
and Box-Behnken experimental design employed 
to optimize the variables, including lubricant 
concentration, mixing time, and compression 
force through investigating their impact on the 
tablet weight, thickness, hardness, friability (%), 
and disintegration time. Moreover, the drug 






The following chemicals were obtained and used 
as received. Fluoxetine HCl was purchased from 
Xi’an Realin Biotechnology Co., Xi’an, China. 
Microcrystalline cellulose was purchased from 
JRS Pharma, Aalen, Germany. Lactose spray 
dried 250 was purchased from DFE pharma, 
Borculo, Netherland. Croscarmellose sodium 
was purchased from FMC Biopolymer, 
Philadelphia, USA. Magnesium stearate was 
purchased from Fisher Scientific, Pittsburgh, PA, 
USA. All chemicals and reagents used were of 
analytical grade. 
 
Flow properties of the powder blend 
 
It is very important to maintain an excellent 
flowability property of the powder blends to keep 
the filling of the punches spaces with the 
required amount of powder during the process of 
tablet compression. Therefore, after weighting 
and mixing the powders together before the 
tablet compression process took place the 
powder flowability should be monitored. Hausner 
ratio, Carr’s index, and angle of repose were 
used to evaluate the flow properties of powders. 
Hausner ratio and Carr’s index were evaluatedby 
monitoring both bulk and tapped volume of the 
powder [23,24]. Bulk density (dB) of the designed 
powder formulation was calculated according to 
the method of Martin et al [25], while tapped 
density (dT) was determined according to Carr 
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[23] and Sheehan [24]. Powder flowability 
properties were determined using Eqs 1 and 2. 
 
Carr’s index = 100(dT  – dB)/dT …………… (1) 
 
Hausner ratio = dB/dT ……………………….. (2) 
 
Angle of repose was calculated using Eq 3 
[24,25]. 
 
Tan (α) = height/0.5 base …………………… (3) 
 
All measurements were carried out in triplicate 
and mean ± standard deviation (SD) computed. 
 
Box–Behnken experimental design 
 
Box–Behnken experimental design (33) of the 
statistical package, Statgraphics® Centurion XV, 
version 15.2.05 (Statpoint Technologies Inc, 
Warrenton, Virginia, USA), was used to assess 
the effects of selected independent variables on 
the variables responses to optimize the ODTs 
formulation procedure. This strategy is used to 
optimize the procedure using a lesser number of 
experimental trials by investigating quadratic 
response surfaces; and for the creation of 
second order polynomial models. The levels of 
factor were coded as low, medium, and high 
settings (−1, 0, and +1) [12,26].  
 
Preliminary experiments revealed that the 
chosen independent and dependent variables 
along with their levels and constraints as shown 
in Table 1 had a significant effect on the ODTs 
formulation. The chosen independent variables 
were the percentage of lubricant concentration 
(X1), mixing time (X2), and compression force 
(X3). The observed responses of the dependent 
variables were the tablets weight (Y1), thickness 
(Y2), hardness (Y3), % friability (Y4), and in-vitro 
disintegration time (Y5). A total of 15 
experimental formulae were planned by Box-
Behnken design (Table 2). 
 
A (33) Box-Behnken design was employed in this 
work and extended to optimize the fluoxetine 
ODTs formulation. Through generating the 
polynomial equations concerning the dependent 
and independent variables, the procedure 
optimized the values of X1, X2, and X3, which 
gave the best wanted possible values of Y1, Y2, 
Y3, and Y4 under controlled circumstances. A 
new formulation was prepared according to the 
predicted levels of X1, X2, and X3. Subsequently, 
the observed responses (Y1, Y2, Y3, Y4, and Y5) 
matched the predicted data and the residual, as 
well as the residual errors (%) were then 
calculated. 
 
Preparation of fluoxetine HCL orally 
disintegrating tablets 
 
Tablets (300 mg) containing fluoxetine HCl were 
manufactured by direct compression method 
under standardized conditions, according to the 
formulation specified in the Box–Behnken design 
(Table 2). Each formulation consisted of 
fluoxetine HCl (6.67 %), microcrystalline 
cellulose (30 %), croscarmellose sodium (4 %), 
and spray dried lactose (to 100 %) and were then 
mixed together for 15 min. Finally, magnesium 
stearate (0.5, 1 or 1.5 %) was added and mixed 
for 2, 13.5 and 25 min. After that 100 g from each 
formulations powder blends were subjected to 
the flowability test. Additionally, the remaining 
formulations powder blends were pressed at 5, 
10 and 15 KN using the rotary tablet press 
(RoTab T, KG Pharma, Berlin, Germany). 
 
Table 1: Independent factors with their levels and dependent variables with their constraints investigated by Box-
Behnken design 
 
Variable Code Units 
Level 
Continuous Low (–1) Medium (0) High (1) 
Independent       
Lubricant concentration X1 % 0.5 1 1.5 Yes 
Mixing time X2 min 2 13.5 25 Yes 
Compression force X3 KN 5 10 15 Yes 
Dependent 
 Code Units 
Constraints (%) Research 
goal Low High 
Weight Y1 mg 299.1 319.2 300 ±7.5% 
Thickness Y2 mm 4.2 4.72 Minimize 
Hardness Y3 Kp 1.2 8.2 Maximize 
Friability Y4 % 0.06 2.5 Minimize 
Disintegration time Y5 sec 11.42 45.45 Minimize 
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Independent variable  Dependent variable 
X1 X2 X3  Y1 Y2 Y3 Y4 Y5 
F1 1.0 25.0 15.0  315.5 4.22 6.3 0.09 31.01 
F2 1.5 2.0 10.0  303.3 4.22 5.1 0.33 25.97 
F3 1.0 25.0 5.0  312.1 4.65 1.3 2.14 12.42 
F4 1.0 2.0 5.0  300.9 4.55 1.8 1.13 11.42 
F5 1.5 13.5 5.0  319.2 4.73 1.4 1.96 12.53 
F6 1.5 25.0 10.0  313.5 4.3 4.5 0.38 25.68 
F7 0.5 2.0 10.0  299.1 4.24 5.3 0.32 20.07 
F8 0.5 13.5 5.0  312.3 4.76 1.2 2.5 11.89 
F9 1.0 2.0 15.0  300.2 4.08 8.2 0.06 40.88 
F10 1.5 13.5 15.0  311.5 4.18 6.6 0.16 45.45 
F11 0.5 13.5 15.0  311.1 4.2 7.3 0.16 27.98 
F12 0.5 25.0 10.0  313.6 4.37 4.5 0.32 19.13 
F13 1.0 13.5 10.0  308.3 4.29 4.4 0.19 22.29 
F14 1.0 13.5 10.0  307.5 4.27 4.3 0.2 22.02 
F15 1.0 13.5 10.0  309.2 4.31 4.5 0.18 22.78 
 
Evaluation of ODT thickness, weight variation 
and hardness 
 
The thickness (mm), uniformity of weight and 
hardness (20 tablets) were determined using 
ERWEKA Multi-Check 5.1 (ERWEKA GmbH, 
Heusensatamm, Germany).  
 
Tablet friability test 
 
Tablet friability (%) was determined using 
ERWEKA, TA3R friabilator (ERWEKA GmbH, 
Heusensatamm, Germany). it rotated for 4 min at 
25 rpm. 
 
Drug content determination 
 
Drug content (10 Tablets) was determined 
according to the USP requirements. Tablets were 
weighed separately, crushed, and the drug was 
extracted with 0.1 N hydrochloric acid, filtered, 
and the content (%) determined by Shimadzu 
UV-1700 spectrophotometer (Shimadzu 
Corporation, Kyoto, Japan) at a wavelength of 
225 nm after suitable dilution [3,16]. 
 
Assessment of in vitro disintegration time 
 
The test was carried out in distilled water 
according to the USP30-NF25 requirements 
using a disintegration tester (ERWEKA GmbH, 
Heusensatamm, Germany). The apparatus was 
maintained at 37 ± 2 °C [27], and the time taken 
for the ODT to pass through the screen or till no 
solid residue remains on the screen was 
recorded as the disintegration time.  
 
In vitro dissolution study 
 
In vitro dissolution was carried out according to 
the USP30-NF25, using an automated 
dissolution tester (ERWEKA, Germany) attached 
to an automated sampler (SP-100 peristaltic 
pump, Somerset, NJ, USA). Dissolution was 
done in 900 mL phosphate buffer at pH of 6.8 ± 
0.05 and 37 ± 0.5 °C temperature to simulate 
saliva fluid. The paddle rotated at 50 rpm. The 
samples were withdrawn automatically after 1, 2, 
3, 4, 5, 10, and 15 min and were analyzed at a 




The designed fluoxetine ODTs formulations 
powder blends were subjected to flowability 
property testing, before their compression into 
ODTs through measuring the Hausner ratio, 
Carr’s index, and angle of repose as displayed in 
Table 3. The 15 formulations powder blends 
displayed a flowability properties ranged from 
good to excellent as seen in Table 3. 
 
ODT weight, as seen in Table 2, ranged between 
299.1–319.2 mg with F5 and F7 respectively. All 
prepared ODTs were around 300 mg ± 7.5 %. 
Accordingly, all the ODT formulations met the 
United States pharmacopoeia requirements 
concerning the homogeneity of weight. 
  
The Pareto chart (Figure 1) showed that variable 
X2 only extended after the reference line and the 
relatively larger coefficient for these terms is 
shown in the regression equation (Eq 4).  
 
Therefore, only the lubricant mixing time (X2) had 
a significant effect on the tablet weight variation 
(Y1) with a positive coefficient. So, X2 displayed a 
direct proportional effect on Y1 for all 
formulations, although the ODT still within the 
USP requirements (±7.5 %). Meanwhile X1 and 
X3 had an insignificant effect on Y1 response. 
Ali et al 
Trop J Pharm Res, April 2016; 15(4): 671  
 




Flowability parameter USP flow 
properties Hausner ratio Carr’s index Angle of repose 
F1 1.24 19.57 30.10 Excellent 
F2 1.33 25.00 32.72 Good 
F3 1.25 19.79 30.54 Excellent 
F4 1.31 23.50 33.10 Good 
F5 1.27 21.54 29.92 Excellent 
F6 1.26 20.83 31.60 Good 
F7 1.47 32.18 35.39 Good 
F8 1.31 23.81 34.77 Good 
F9 1.33 25.00 32.41 Good 
F10 1.28 21.88 29.48 Excellent 
F11 1.30 23.10 35.14 Good 
F12 1.35 25.81 33.25 Good 
F13 1.24 19.44 30.98 Excellent 
F14 1.25 19.89 29.78 Excellent 
F15 1.24 19.47 29.92 Excellent 
 
 
Figure 1: The Pareto charts that represent the relationship of various levels of independent factors to achieve 
fixed values of Y1–5 responses 
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Y1 =310.962 – 11.9428X1 + 1.33677X2 – 
1.96732X3 + 11.2833X12 – 0.186957X1X2 – 
0.55X1X3 – 0.0285759X22 +  0.0178261X2X3 + 
0.104833 X32 …………………… (4) 
 
where X12, quadratic term of lubricant 
concentration; X22,quadratic term of mixing time; 
X32, quadratic term of compression force; X1X2, 
interaction between lubricant concentration and 
mixing time; X1X3, interaction between lubricant 
concentration and compression force; X2X3, 
interaction between mixing time and 
compression force; Y1, tablet weight variation 
(mg); Y2, tablet thickness (mm); Y3, tablet 
hardness (Kp); Y4, friability (%); and Y5, in vitro 
disintegration time (sec). 
 
Table 4 and Figures 1 – 3 indicate that Pvalue of 
X2 <0.05 and the Fratio was 73.47 (highest value) 
so it had a significant effect. The Pvalues of X1 and 
X3 were >0.05 and the Fratios were 3.03 and 1.45 
(lowest values) so they had an insignificant 
effect. Moreover, fluoxetine content uniformity 
within all ODT formulations ranged from 97.72 ± 
2.97 to 103.6 ± 1.85 %. Therefore, fluoxetine 
content distributed homogeneously throughout all 
suggested prepared formulations. 
 
Tablet thickness (Y2) measurements were 
displayed in Tables 2, 4 and Figures 1 – 3. 
Y2 ranged from 4.08mm to 4.76mm with F9 
and F8, respectively. Pareto chart and 
estimates calculated showed the priority 
effect of X3 over other independent variables, 
the bars of X3 and X2 extended after the 
reference line accompanied with a negative 
coefficient of X3 and positive coefficient of 
X2. The relatively larger coefficient of these 
variables is seen in the regression equation 
for Y2 as shown below (Eq. 5): 
 
Y2 = 5.40669 – 0.355652X1 + 0.015534X2 –
0.161598X3 + 0.17X12 –0.00217391X1X2 + 
0.001X1X3 – 0.000378072X22 + 0.000173913X2X3 
+ 0.0054X32 …………………(5) 
 
Calculated p-values were < 0.05, plus the Fratios 
were 19.1 and 381.14 for X2 and X3 respectively. 
Therefore, X3 had the highest priority effect than 
other independent variables and accompanied by 
an inverse proportional effect on Y2 while X2 was 
in the second priority effect. Whereas p-value of 
X1 was > 0.05 and it accompanied with a very 
low Fratio (1.85). Consequently, increasing X2 and 
X3 and led to the decreasing of Y2.  
 
Tablet hardness responses (Y3) were displayed 
in Tables 2, 4 and Figures 1 – 3. The lowest Y3 
was reported with F8 (1.2 Kp) but the highest Y3 
was reported with F9 (8.2 Kp). Additionally, the 
Pareto chart showed the variables of X2 and X3 
bars were extended after the reference line and 
the relatively larger coefficient for these terms is 
shown in the regression equation as below (Eq 
6). 
 
Y3 = –2.74719 – 0.0923913X1 – 0.063138X2 + 
1.02967X3 + 0.35X12 + 0.00869565X1X2 – 
0.09X1X3 + 0.00274102X22 – 0.00608696X2X3 – 
0.0145X32 ………..(6) 
 
X3 exhibited positive coefficient while X2 acquired 
negative coefficient. The p-values for X2 and X3 
were < 0.05 while F ratios was 57.3 and 2044.8, 
respectively, indicating a significant effect of 
those variables on Y3 while the calculated Pvalue 
of X1 was >0.05 and the Fratio was very low 
(1.94). Therefore, Y3 was closely related to the 
increase of X2 and X3 [29]. 
Table 4: Calculated estimates, P-values and F-ratios for Y1–5 responses 
 
Response X1 X2 X3 X12 X1 X2 X1 X3 X22 X2 X3 X32 
Y1 Estimate 2.6 12.8 –1.8 5.642 –2.15 –2.75 –7.558 2.05 5.242 
Fratio 3.03 73.47 1.45 6.59 1.04 1.70 11.82 0.94 5.69 
Pvalue 0.142 0.0004* 0.282 0.050 0.355 0.250 0.019* 0.376 0.063 
Y2 Estimate –0.035 0.113 –0.503 0.085 –0.025 0.005 –0.1 0.02 0.27 
Fratio 1.85 19.10 381.14 5.03 0.47 0.02 6.97 0.30 50.79 
Pvalue 0.232 0.007* 0.0001* 0.075 0.523 0.896 0.046* 0.606 0.001* 
Y3 Estimate –0.175 –0.95 5.675 0.175 0.1 –0.45 0.725 –0.7 –0.725 
Fratio 1.94 57.30 2044.8 0.90 0.32 6.43 15.40 15.56 15.40 
Pvalue 0.222 0.0006* 0.0001* 0.387 0.598 0.052 0.011* 0.011* 0.011* 
Y4 Estimate –0.117 0.273 –1.815 0.488 0.025 0.27 –0.193 –0.49 1.5225 
Fratio 0.46 2.48 110.07 3.67 0.01 1.22 0.57 4.01 35.75 
Pvalue 0.527 0.176 0.0001* 0.114 0.923 0.320 0.484 0.102 0.002* 
Y5 Estimate 7.64 –2.525 24.265 0.879 0.325 8.415 –0.181 –5.435 3.319 
Fratio 49.83 5.44 502.69 0.30 0.05 30.23 0.01 12.61 4.34 
Pvalue 0.0009* 0.067 0.0001* 0.605 0.840 0.002* 0.914 0.016* 0.092 
* Significant effect of factor on individual response 
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Likewise, tablet friability (%) responses (Y4) were 
displayed in Tables 2 and 4 and Figures 1 – 3. It 
ranged from 0.06–2.5% (F9 and F8 respectively). 
The X3 had an inverse effect on Y4 where its bar 
extended after the reference line and the 
relatively larger coefficient for this term is shown 
in the regression equation as below (Eq. 7):  
 
Y4 =5.84405 – 2.63685X1 + 0.0719329X2 – 
0.786978X3 + 0.975X12 + 0.00217391X1X2 + 
0.054X1X3 – 0.000727788X22 – 0.00426087X2X3 + 
0.03045X32 ……………………(7) 
 
However, X1 and X2 had an insignificant effect on 
Y4 response. Furthermore, the Pvalues were <0.05 
and the Fratio (110.07) were the highest among all 
other variables effect. On the other hand, the 
Pvalues for X1 and X2 were >0.05 and the Fratios 
were 0.46 and 2.48 respectively, which were 
lower than the value of X3 (110.07) reported. This 
indicated that X1 and X2 had insignificant and low 
priority effect on Y4. Therefore, the tablets that 
were prepared at stronger X3 presented lower Y4 
due to the hardness and thickness [29]. 
 
The time of disintegration (Y5) responses were 
seen in Tables 2, 4 and Figures 1 – 3. F4 
exhibited the lowest Y5 (11.42 s) but the highest 
was noticed with F10 (45.45 s) in which the Y5 
regression equation (Eq. 8):  
 
Y5 =11.0438 – 13.0882X1 + 0.353025X2 + 
0.0538551X3 + 1.75833X12 + 0.0282609X1X2 + 
1.683X1X3 – 0.00068368 X22 – 0.0472609X2X3 + 
0.0663833 X32  …………………..(8) 
 
 
Figure 2: 3D response surface plots represent the relationship of different levels of independent factors to 
achieve the fixed values of Y1–5 responses 
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Figure 3: Contours surface response plots represent the relationship of different levels of independent factors to 
achieve the fixed values of Y1–5 responses 
 
The positive coefficient of X1 and X3 
demonstrated direct proportional effect plus high 
priority effect of X3 compared to X1 on Y5 as 
displayed. The Pvalues of X1 and X3 were < 0.05. 
The Pvalue of X2 was > 0.05 which indicated an 
insignificant effect on Y5. Additionally, the Fratios 
of X1, X2, and X3 were 49.83, 5.44, and 502.69 
respectively. These results are in accordance 
with the findings of other works [29]. 
 
All formulations achieved T50 (time of 50 % of 
fluoxetine release) within the first minute while 
T80 (time of 80 % of fluoxetine release) was 
achieved by F4 and F8 within 1 min. The 
dissolution of the 15 formulations after 5 min 
ranged from 71.45 - 96.73 %. After 10 min, the 
values ranged from 78.56 – 100.00 %; while after 
15 min, dissolution from almost all formulations 
approximately 100 %. Figure 4 showed the 
dissolution profile of selected formulations. This 
selection is based on the fact that these selected 
formulations showed the effect of X1, X2, and X3 
employed without repeating the results for the 





The powder blends displayed acceptable 
flowability property which ranged from good to  
Ali et al 
Trop J Pharm Res, April 2016; 15(4): 675  
 
 
          Figure 4: Dissolution profiles for some selected formulations 
 
excellent [23,24]. Magnesium stearate particles 
formed a thin layer covering the other powder 
particles that improved the powder flowability 
properties, especially with higher concentration 
(1.5 %). The longer mixing time (13.5 and 25 
min) enabled the lubricant particles to fill all 
groves over the powder blend particles surface 
and form an intact thin layer over the  particles 
surfaces [9]. 
  
Tablet weight variation is closely correlated with 
the increase of lubricant mixing time due to the 
presence of lubricant material like magnesium 
stearate within the powder blend. Besides, the 
mixing time allowed the lubricant particles to 
spread efficiently throughout the tablet 
ingredients particles forming a thin layer over 
these particles, that leads to minimum particles 
interaction and friction and consequently 
improving the flowability properties [7]. The 
punches spaces of tablet press machine were 
filled with powder particles without pressure only 
with the powder flowability effect. Therefore, 
excellent powder flowability property is 
considered as a requirement for the successful 
direct compression technique [9]. Excellent 
powder flowability property reduced the particle 
friction so particles moved easily over each 
other. So, the particle-particle spaces might be 
reduced to its minimum, leaving more spaces 
that could be filled with excess particles between 
the punches spaces instead of air that might 
explain the tablet weight increase. At the same 
time the ODTs weight is controlled by the 
punches spaces that were adjusted before 
commencing the compression process. 
Consequently, the ODTs weights were not very 
noticeable, but they were around 300 mg ± 7.5 % 
[24]. 
 
Tablets thickness is mainly influenced by the 
increase in compression force and the decrease 
of mixing time since the decrease of powder 
flowability property leads to the decrease of 
particles content. Tablet hardness is also strictly 
associated with the increase of compression 
force and the decrease of mixing time as 
reported by Andries et al [29]. Tablet friability is 
affected by the compression force employed 
during tablets pressing in which leads to harder 
tablets. Disintegration time is thoroughly related 
to the increase in lubricant concentration and 
compression force, but it is not influenced by the 
length of mixing time. It might be due to the 
decrease of tablets friability % and hardness as 
reported tby others [29].  
 
Fluoxetine tablet content was uniformly 
distributed throughout the formulation and the 
direct compression technique displayed an 
efficient procedure for the manufacturing of 
fluoxetine HCl ODTs.  
 
The fluoxetine release (%) was very high within 
the first minute of dissolution, then T80 was 
noticed within 5 min of dissolution with those 
formulations that had the smallest lubricant 
concentration, shortest mixing time, and lowest 
compression force (Figure 4). Consequently, 
lubricant concentration, mixing time, and 
compression force influenced the fluoxetine 
release (%) due to the hydrophobic property of 
magnesium stearate, since it forms a layer over 
the particulates and stronger compression force 
increases the tablets hardness as reported by 
others [29].  
 
The goal of this work was to prepare an 
optimized fluoxetine ODTs formula with an 
average weight of 300 mg ± 7.5%, minimum  
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Factors Predicted Observed Residuals 
Prediction 
Error (%) 
X1 0.86 Y1 309.15 308.2 0.95 0.31 
X2 15.3 Y2 4.28 4.3 – 0.02 – 0.4 
X3 10.6 Y3 4.7 4.6 0.1 2.13 
  Y4 0.135 0.129 0.006 4.44 
  Y5 22.4 21.6 0.8 3.57 
 
tablet thickness, friability (%), and disintegration 
time, but accompanied with maximum tablet 
hardness. The optimum responses of the 
variables were gained through graphical and 
numerical analysis by means of statistical 
Statgraphics® software and based on the 
principle of desirability [30]. The Box-Behnken 
design has suggested an optimized formula as in 
Table 5. 
 
Therefore, the suggested formula was prepared 
and then characterized as done before. The 
experimental results were compared to the 
design predicted results by calculating the 
residual and residual error (%) in order to 
validate the Box-Behnken design suggestion. 
The residual differences were 0.95 mg, –0.02 
mm, 0.1 Kp, 0.006 %, and 0.8 s respectively, and 
the prediction errors (%) were 0.31, –0.4, 2.13, 
4.44, and 3.57 %, respectively. The results 
showed an insignificant difference (t-test, Pvalue > 
0.05) between the predicted and experimental 
responses (Table 5). The suggested optimal 
formula showed the best-fitted formula amongst 
other formulae according to the prediction error 
(%) and/or residual results which were below 5 % 




Fluoxetine ODTs have been successfully 
developed and improved by a Box-Behnken 
experimental design, and prepared using direct 
compression technique. Variables including 
lubricant concentration, mixing time, and 
compression force have a quantitative effect on 
the weight variation, thickness, hardness, 
friability (%), and in vitro disintegration time 
which could be predicted by Box-Behnken 
design.  
 
The experimental values of the improved formula 
were close and in line with the predicted values 
that verified the integrity of the developed 
fluoxetine ODTs formulation. Finally, this 
optimized and developed antidepressant drug, 
fluoxetine HCl, ODTs formulation will achieve 
numerous targeted benefits such as rapid onset 
of action, high bioavailability, ease of 
administration, and patients’ convenience, 
especially for those with swallowing difficulties 
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